Document is current
Any future updates will be listed below
-
Authors
Kong, Sek Won https://orcid.org/0000-0003-4877-7567
Lee, In-Hee https://orcid.org/0000-0002-8857-1355
Collen, Lauren V.
Field, Michael https://orcid.org/0000-0002-4003-0568
Manrai, Arjun K.
Snapper, Scott B. https://orcid.org/0000-0003-0267-4247
Mandl, Kenneth D.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (U01TR002623, U01TR002623)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS129188)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U54HG012513)
PrecisionLink Health Discovery and Children’s Rare Disease Cohorts initiative of Boston Children’s Hospital
Helmsley Charitable Trust, Wolpow Family Chair in IBD Research and Treatment, Egan Family Foundation Chair in Transitional Medicine
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 14 February 2025
First Online: 28 February 2025
Competing interests
: S.K. reported grants from Pfizer and Quest Diagnostics. S.B.S. declares the following interests: scientific advisory board participation for Pfizer, Merck, Dualyx, Sonoma Biotherapeutics, Spyre Therapeutics, and Biolojic Design; grant support from Pfizer, Novartis, Amgen. No other disclosures were reported.
